kstew call note call focus deliveri
management comment would comment
baxter report result morn hich view ed disappoint share ere trade low er reaction
et dow versu compani finish earn confer call coupl
takeaw ay call thought net/net view remain unchang believ expect ere high
medic deliveri issu persist key focu manag note mis-model busi
distributor de-stock took place also comment made manag chang busi baxter
expect medic deliveri sale declin low singl digit versu prior guidanc grow th manag note
 ith base year reset could still achiev long rang plan lrp goal hich grow th
 baxter look bigger broader manag comment say agnost hen come deal size
 ith constraint ant stay invest grade note could push bound manag also
comment ould look adjac core potenti outsid core anoth leg note ould look
implement cost transform baxter ere natur synergi
outlook baxter guid ep hich street estim manag note impact
relat medic deliveri nutrit busi that per share impact offset save
initi cyclo coupl financi adjust ith foreign exchang tax combin
reduc expect fa see tax uplift manag comment expect ere dow roughli
midpoint midpoint
comment outlook stay tune januari earn releas manag refrain offer
commentari outlook said investor need ait releas result januari note
numer put take given year prematur give guidanc point manag reaffirm
commit lrp hich gave specif target note street ep estim
high end lrp
pleas feel free reach ith question
ps raw note verbatim apolog typo growth rate constant currenc unless otherwis
solid perform sale report cc oper ep ere y/i strong earn grow th
demonstr pow er oper improv initi see potenti effort go forw ard
driver grow th renal care pharmaceut advanc surgeri contract manufactur help off-set declin med
deliveri nutrit
renal care driven increas patient volum periton dialysi pd doubl digit pd grow th us experienc posit
patient grow th japan pharma strength us increas demand premix inject clari continu deliv
doubl digit sale grow th receiv approv prismax next gener crrt technolog
us medic deliveri nutrit busi disappoint suppli disrupt ith hurrican maria market
dynam fundament shift segment resum reduct pre-hurrican level custom demand
fulli resum prior level ith respect small volum parent mini-bag line move iv push administr
drug competit product select us nutrit product seen market contract hether delay start and/or
dose shift outsourc compound competitor product expect resum low digit market grow th come
quarter larg volum iv solut spike first month year result grow ing inventori level didnt forecast
destock suppli constraint eas end user demand lv busi ytd hich believ ahead
market hich estim grow ing reset expect busi go forw ard medic nutrit
busi ill grow line ith long-term outlook
although experienc challeng market dynam select busi result reflect benefit diversif effort drive
sale billion ere report constant currenc cc oper basi
ep ere per share driven solid on-going oper perform low er tax rate
america cc oper emea cc oper asiapac flat cc oper basi
sale intern compound busi due earli settlement australia impact grow th
renal care cc basi perform driven msd pd therapi ith lsd global center hd busi
medic deliveri dow cc driven busi dynam mention earlier
pharma cc oper benefit anesthesia increas pre-fil drug demand cyclo
nutrit dow cc basi solid grow th ou off-set low er sale us
advanc cc oper recothrom preveleak sale ere
acut therapi cc basi continu dd grow th trend increas global demand crrt
primarili contract manufactur cc driven increas demand cm servic cytotox servic
adjust gp benefit favor product mix manufactur effici
sg spend dow report flat cc basi continu see posit contribut expens manag
busi transform initi off-set loss busi transit shire recent acquisit
 report cc basi continu invest high impact program
op margin versu prior year grow th driven strong oper expans continu expens management
net interest higher interest incom due rate
adjust tax rate quarter stock compens favor expect discret item quarter
share repurchas quarter partial off-set option relat dilut
flow ith improv net incom off-set higher inventori level
lower sale forecast expect full year sale report basi cc basi oper basi note
downward revis prior guidanc constant currenc oper growth
renal care expect sale grow th note consist prior guidanc
deliveri low singl digit declin note reduct prior guidanc
pharma expect high singl digit constant currenc grow th assum cyclo sale previou sale guidanc
continu expect clari sale adjust cyclo month clari expect oper grow th
note higher prior guidanc
nutrit expect sale declin low singl digit note downward revis prior guidanc
advanc surgeri expect sale cc basi includ acquisit recothrom preveleak
oper basi expect sale note upward revis prior guidanc
acut therapi expect sale grow th note slight upward revis prior guidanc
busi expect high singl digit sale grow th due increas demand contract manufactur note upward
revis prior growth
tax year adjust tax rate
ep expect note high end prior rang
year expect ocf ith capital-expenditure dow slightli prior guidanc due higher inventori level
note prior guidanc ocf
expect sale report cc oper basi
question answer question manag respons verbatim
issu seem bit structur quantifi degre lose share may impact
 ere shift market us mini-bag mini-bag plu amino acid ere one
teach use altern method expect come back other ill take littl longer come back dont
see issu ere experienc rebas busi affect grow th rate go forw ard full year
result base lrp may hich use revis long term guidanc plan baxter
either top bottom line lost custom may lost temporari share account fluid
substitut small volum parent use administ infus medicin patient dose ere
infus mini-bag find ay administ portion ent iv push practic nurs take
syring dilut drug inject port ith access vein time custom move
iv push chang protocol believ get back take time other ent competit product feel good
 get back nutrit impact hurrican market contract hen custom didnt product
delay start time think market contract also lost share didnt product dont think long term
piec next quarter think ramp see product back anyth like chang protocol take time
time aggress buy-back ill look capac use signific amount
effort ant make sure capac buy back share go
renew ed focus effort baxter
lvp trend lvp good understand hat happen ith stock destock havent lost
custom pattern purchas alloc ould buy lot suppli first time
market ith alloc go new era lvp plant remedi improv output resolv long last
qualiti issu capac mexico ireland execut issu short term team didnt understand
inventori demand didnt see signal commun effect made chang us
team lvp busi highli success baxter lot new custom sign up
tremend market shift last year coupl ith industri challeng suppli custom purchas everyth could
produc product alloc brought product latin america could bring product
demand product tremend particularli custom purchas end user demand distributor ork
inventori believ close back equilibrium end user demand get trace report
sv iv push packag insert administr put mini bag infus min inject iv push ith
 ill min period time studi show lot time dont ait long push could
prescript dose medic error comfort ith iv push drug best ay administ
mini-bag
guidanc year confirm overal guidanc high end rang guidanc dow
rel hat previous share issu highlight ith medic deliveri nutrit impact that
impact offset save initi cyclo coupl financi adjust ith foreign exchang
tax reduc expect fa see tax uplift roughli dow midpoint midpoint
believ real opportun recov far specif guidanc ill stop short
reiter confid long rang plan ith number
acut therapi pharmaceut help us understand what drive excel perform abl
produc product other cant exampl cyclo difficult manufactur brevibloc dont see product
repeat perform time brevibloc coupl manufactur market baxter ill look acquir
molecul commit deliv lrp acut therapi launch prismax therapi around
globe continu success gain share ould sell premix ould sell day eek svp
galaxi product hat told substitut hen didnt mini-bag plu
infus system done ytd system launch continu believ pick market share unit
state found ith custom sell cycl lengthen littl bit reduc pump number littl bit slip
next year
lvp price ytd price situat look product longer term contract
modest price increas built
flow still healthi grow th adjust inventori build fall short sale forecast difficult adjust inventori
plan avoid inventori build also select product make inventori build expect
structur think progress seen extraordinari grow th ith might
svp manufactur dynam pr product level back ant need ere abl put mini-bag back
channel mid-juli bag plu channel septemb healthi code
assumpt inventori custom chase inventori look trace data get comfort
think custom spent lot time ith bottom line build includ lvp svp recaptur think
right number look launch singl pack mini bag plu castlebar facil diversifi risk ith
headwind help us think tune jan ill guidanc share
financi guid post numer put take look given year prematur give
guidanc point
 baxter agnost deal size anyth chang look opportun adjac core
complet outsid core term anoth leg stool take constraint size look everi opportun
 ill get us need go hich refresh portfolio baxter creat momentum gross margin accret
top line bottom line ill push boundari debt ratio limit invest grade
creat size limit hat baxter done ith busi transform oper incom
transform compani difficult achiev learn know paramount import
context abil go compani look multipl size deal adjac outsid core
 ithin healthcar look extract cost compani even core synergist us
nutrit protocol chang term delay start influenc guidelin ere ritten conserv
mode sick patient difficult track outcom data show outcom better hen
nutrit appropri market contract ill ork bring back
manag chang follow forecast misstep plan alw ay look execut baxter
straightforw ard thing expect straightforw ard understand market import signific chang
 ere made busi significantli manag chang saw busi better issu
 ith medic deliveri made chang
gross margin expans y/i compon drove lion share relat cost initi busi
transform margin journey initi focus sg that faster take
abl make chang netw ork margin improv relat cost initi mix oper
grow th expect see progress ith drive cost ith come gross margin
number new product benefit think look year go
grow th question much go go someth talk januari count kayuga
next year count new product ithout doubt go execut new product
revit focu made revit think transform three differ phase
 come put organ structur get done team ork dilig find
opportun couldnt come month job didnt balanc sheet strategi compet leader
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
